Ironwood Pharmaceuticals (IRWD) Institutional Ownership

During the previous two years, 231 institutional investors and hedge funds held shares of Ironwood Pharmaceuticals. The most heavily invested institutionals were Vanguard Group Inc. ($86.56M), Wellington Management Group LLP ($65.00M), Pacer Advisors Inc. ($51.97M), Armistice Capital LLC ($50.86M), State Street Corp ($40.87M), Renaissance Technologies LLC ($40.16M), and Adage Capital Partners GP L.L.C. ($23.71M).Learn more on IRWD's institutional investors.

Of the 185 institutional investors that purchased Ironwood Pharmaceuticals stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Armistice Capital LLC ($8.10M), Pacer Advisors Inc. ($5.44M), Vanguard Group Inc. ($4.67M), Jacobs Levy Equity Management Inc. ($3.60M), Renaissance Technologies LLC ($2.62M), Jupiter Asset Management Ltd. ($2.07M), and Kynam Capital Management LP ($1.63M).

Institutional investors have bought a total of 55,548,853 shares in the last 24 months. This purchase volume represents approximately $460.57M in transactions.

Of the 122 institutional investors that sold Ironwood Pharmaceuticals stock in the last 24 months, the following investors and hedge funds have sold the highest volume of shares: Bank of Montreal Can ($8.42M), Wellington Management Group LLP ($7.16M), LSV Asset Management ($2.92M), Vanguard Group Inc. ($2.50M), Dimensional Fund Advisors LP ($2.44M), Royce & Associates LP ($1.60M), and Brown Capital Management LLC ($1.26M).

Institutional investors have sold a total of 39,929,749 shares in the last 24 months. This volume of shares sold represents approximately $321.67M in transactions.